Cardio AI


Diagnos Inc. (ADK.V) has provided more details with regard to the news release issued earlier today for the signing of a memorandum of understanding between one hospital in the United States and Diagnos.

Memorandum of understanding

Main terms:

  • Date of signature: March 22, 2019;
  • Partner and Diagnos agree to negotiate, in good faith, a specific agreement for establishing cooperative development and marketing effort for:
    • Any required development and inter-operability testing of CARDIO;
    • The granting of access to each Party's facilities;
    • The co-marketing of CARDIO.

Diagnos expects to sign a definitive agreement with Partner within 45 days from the date of this news release.


CARDIO is a software application, currently under development, to assist the health professionals in predicting the risk of a patient having a stroke or other conditions that may lead to a stroke. CARDIO was first announced in a press release dated September 19, 2017. Diagnos foresees full commercial deployment of CARDIO within six to twelve months from the date of this news release.

About Diagnos

Diagnos is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence ("AI") tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA's Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.